[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564758":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":36,"responsibleParty":56,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":31,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":31,"maxAge":31,"enrollmentInfo":71,"targetDuration":31,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":39,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of CD5+ T-lymphoma Targeted CAR T-cells","EXPERIMENTAL","Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.",[13],"Biological: CD5 CAR T-cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CD5 CAR T-cells","Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion",[9],[21],"CD5+ T-lymphoma Targeted CAR T-cells injection",[23],{"name":24,"affiliation":25,"role":26},"He Huang, MD","First Affiliated Hospital of Zhejiang University","PRINCIPAL_INVESTIGATOR",[28,33],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","057187233772",null,"hehuangyu@126.com",{"name":34,"role":29,"phone":30,"phoneExt":31,"email":35},"Yongxian Hu, MD","huyongxian2000@aliyun.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The first affiliated hospital of medical college of zhejiang university","RECRUITING","Hangzhou","Zhejiang","310003","China","CN",{"type":46,"coordinates":47},"Point",[48,49],120.16142,30.29365,{"lat":49,"lon":48},[52,54],{"name":53,"role":29,"phone":30,"phoneExt":31,"email":32},"He Huang, PhD",{"name":55,"role":29,"phone":30,"phoneExt":31,"email":35},"Yongxian Hu, PhD",{"type":26,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"He Huang","Clinical Professor",[60],{"name":61,"class":62},"Yake Biotechnology Ltd.","INDUSTRY","100564758","early-phase-1-targeting-cd5-car-t-cells-in-the-treatment-of-rr-cd5-t-lymphoma-100564758",false,"NCT06633341","Targeting CD5 CAR-T Cells in the Treatment of r\u002Fr CD5+ T-lymphoma","A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r\u002Fr CD5+ T-lymphoma","Inclusion Criteria:\n\n* 1\\. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),\n\nR\u002FR T-NHL(meets one of the following conditions) :\n\n1. Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;\n2. Primary drug resistance;\n3. Relapse after autologous hematopoietic stem cell transplantation;\n\n   * 2.CD5 expression rate was \\>90%;\n   * 3\\. According to Lugano 2014, there should be at least one evaluable tumor lesion;\n   * 4\\. Total bilirubin ≤51 (mol\u002FL), Alanine aminotransferase (ALT)\u002FAspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol\u002FL);\n   * 5\\. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;\n   * 6\\. Refers to the pulse oxygen saturation 92% or higher oxygen (state);\n   * 7\\. Estimated life expectancy of minimum of 12 weeks;\n   * 8\\. ECOG 0-2;\n   * 9\\. Pregnant\u002Flactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;\n   * 10\\. Those who voluntarily participated in this trial and provided informed consent;\n\nExclusion Criteria:\n\n* 1\\. History of epilepsy or other central nervous system disorders;\n* 2\\. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n* 3\\. Active infection of hepatitis B virus, C virus or hepatitis E virus;\n* 4\\. Active infected persons who are not cured;\n* 5\\. Before using any gene therapy products;\n* 6\\. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:\n\n  1. treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone \\\u003C 10 mg\u002Fd or an equivalent dose of the drug);\n  2. received within 72 hours of small molecule targeted therapy;\n  3. 2 weeks received systemic chemotherapy except (pretreatment);\n  4. four weeks received radiotherapy;\n* 7\\. The proiferation rate is less than 5 times response to CD3\u002FCD28 co-stimulation signal;\n* 8\\. Any unsuitable to participate in this trial judged by the investigator;\n* 9\\. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.","ALL",{"count":72,"type":73},30,"ESTIMATED","INTERVENTIONAL",[76],"EARLY_PHASE1","A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r\u002Fr CD5+ T-lymphoma",[79],"T-lymphoblastic Lymphoma",[81],"CD5 CAR-T","2024-10-08",{"date":84,"type":85},"2024-10-09","ACTUAL",{"date":87,"type":73},"2024-10-20",{"date":89,"type":73},"2027-10-20",{"name":5,"class":6},1]